Karen D. Corbin PhD, RD
Investigator, AdventHealth Translational Research Institute for Metabolism and Diabetes, Orlando, FloridaDr. Corbin is an Investigator at the AdventHealth Translational Research Institute (TRI). Her research focuses on enterohepatic metabolism and the mechanisms that drive individual susceptibility to metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), diabetes and obesity. Her research portfolio includes both investigator-initiated and industry clinical-translational studies focused on novel pathogenic mechanisms and therapeutics.
Dr. Corbin came to the TRI after a 3-year term as a Research Assistant Professor at UNC Chapel Hill, Gillings School of Global Public Health, Department of Nutrition. She conducted both her faculty and post-doctoral research at the UNC Nutrition Research Institute in Kannapolis, NC. Her research was dedicated to understanding individual differences nutrient requirements and how those differences influenced metabolic diseases such as obesity, diabetes and NAFLD. Dr. Corbin earned her doctorate degree in molecular medicine at the University of South Florida College of Medicine in 2008. She became a registered dietitian in 1998 after completing her dietetic internship at the James A. Haley Veteran’s Hospital in Tampa, FL. She earned her Bachelor’s Degree in Nutrition and Food Science in 1997 at Florida State University.
Recent Contributions to PracticeUpdate:
- Effectiveness of SGLT2 Inhibitors vs DPP-4 Inhibitors on Liver Function in Patients With Type 2 Diabetes in Japan
- Performance of Non-Invasive Fibrosis Scores in NAFLD With and Without Morbid Obesity
- Screening Strategies for NAFLD in T2D
- Dapagliflozin Shows Potential for Hepatic Steatosis and Fibrosis
- Type 1 Diabetes and Hepatic Steatosis